Don Robbins, President and CEO of CSMG Technologies, said, “We are pleased that we are able to continuously expand our patent portfolio, adding new surgery specific instruments designed for use with the LTC electrosurgery generator. We believe the LTC technology, along with the underlying intellectual property, allows us the opportunity to make significant advances in the worldwide surgery markets. Having received the CE Mark approval on the electrosurgery generator and with commercial manufacturing of instruments and generator in-process, we hope to enter the European markets toward the end of this quarter or early next quarter.”

LTC’s Frank D’Amelio added, “These patent applications are related to our to-be-released new line of disposable bipolar sealing hemostats. Expanding our IP portfolio is a priority for the LTC management team in 2008. These four applications are a great start for our intellectual property pipeline. The concepts described and the claims within these applications were possible as a result of what we believe to be excellent and unique designs coming out of our design house, ViR Engineering.”

About Live Tissue Connect

LTC's surgical tissue bonding / welding device is a patented platform technology that bonds and reconnects human soft tissue through fusion, in contrast with conventional wound closing devices such as sutures, staples, sealant, or glues. LTC currently holds a total of approximately 44 patents and patent applications in the U.S., Australia, Canada, European Union, Ukraine and other countries.

For further information on CSMG Technologies and its various subsidiaries, please visit our website at www.csmgtechinternational.com.